Navigation Links
ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO

-- Genotypically Optimized Dosing Results in Improved Tolerance and Evidence of Anticancer Activity --

MELBOURNE, Australia, and MENLO PARK, California U.S.A. June 04, 2007-ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of data from its Quinamed (amonafide dihydrochloride) phase 1/2a dose-escalation study, designed to identify a genotypically optimised dose of Quinamed in heavily pre-treated patients with a variety of solid tumors. The key outcomes from this study were (i) demonstration that dose level could be optimised according to patient genotype, (ii) the drug was well tolerated, with predictable and manageable side effects, and (iii) there was evidence of anticancer activity in several solid tumor types.

Dr. John Kuhn of the University of Texas Health Science Center in San Antonio, TX, along with the investigators at Sarah Cannon Cancer Center, TN and University of Louisville, KY discussed the data in an oral presentation at the American Association of Clinical Oncology (ASCO) 43rd Annual Meeting in Chicago, Illinois.

“The clinical activity of amonafide against a variety of cancers has long been recognized, but development has been hampered by the unpredictable side effect profile for patients” said Dr Kuhn. “We are excited by the new opportunities that personalized dosing of Quinamed offers for a range of solid tumor patients who have developed resistance to existing therapies.”

Highlights of the presentation included:

Confirmation that genotyping of patients prior to treatment allows for optimized personalized dosing and improved drug tolerance.

Patients with rapid and intermediate acetylator genotypes (who more rapidly metabolize the drug to the acetylated derivative associated with side effects) achieved a maximum tolerated dose (MTD) of 320 mg/m2 of Quinamed weekly, whilst patients with slow acetyla
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:11/25/2008)...spondents against expanding statin use broadly in ...S, N.J., Nov. 25 JUPITER, a clinic...diovascular risk of healthy patients with elevated...der adults, according to a national poll directed ...ook part in the online poll conducted by medical n...
(Date:11/25/2008).... 25 Pharmacyclics, Inc....ny has completed a Phase 1,clinical trial with PC...l-molecule Factor VIIa inhibitor. The trial was co...luate the safety and pharmacologic effect of,PCI-...ed in a linear dose,response in the International...
(Date:11/24/2008)...SAKA, Japan, Nov. 24 Takeda Pharma...idiary, Takeda Global Research & Development C...tis Advisory Committee of the U.S. Food and Drug A...ve febuxostat for the treatment of hyperuricemia ...favor of approval, with one panel member abstainin...
(Date:11/24/2008)... Cancer Awareness Month , , Oak Brook, Ill.... Society for Gastrointestinal Endoscopy (ASGE) and...up this November to raise awareness about pancreat...d the resources that are available for them. , ...e of cancer deaths in the U.S. In 2008, an estimat...
Breaking Medicine Technology:Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 1New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 2New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 3New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability Would Rely on Sources Other than Themselves for S 19037 4History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 1History Making Obesity Awareness Event Scheduled to Take Place in Washington DC on June 17 2008 19035 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 1Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 2Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 3Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 4Shire Launches Nationwide Adult ADHD Mobile Awareness Tour 5312 5Ancient protein offers clues to killer condition 3266 1Ancient protein offers clues to killer condition 3266 2
...720 Mechanisms in Multiple,Sclerosis May Include D... studies suggest FTY720 stimulates cells,that may ...f the,CNS affected by multiple sclerosis , ·...,sclerosis Phase II clinical study found that the ...s significantly lower in the,FTY720 groups compare...
...)--May 4, 2007 - New data from a,randomized, doubl...E(R) (glatiramer acetate injection) along with the... (Gd)-enhancing lesions,of the brain by 63 percent...ing multiple sclerosis (RRMS), as measured by,magn...ceiving,COPAXONE(R) alone. Additionally, the nine-...
Other Medicine Technology:Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
(Date:12/2/2008)...g Improves Service and Efficiency by Automating Ac...NGHAM, Mass., Dec. 2 Courion(R) C...liance, today announced that Brookdale Senior Livi...ior living communities, has deployed Courion,s Ent...ecure access to enterprise applications and other ...
(Date:12/2/2008)...rate With Traditional Holiday Cuisine , , M...inistries ( www.angelfoodministries.com ), an orga...at low-costs, to anyone who wishes to participate,... a specialty Christmas Box which includes everythi...ost sites are now taking orders throughout the cou...
(Date:12/2/2008)...and Professionals Shares Experience , Dealing w...ation, More , , WASHINGTON, Dec. 2 /PRNewsw...nal disability association working on equity, dive...cant disabilities announces the official launch of...ry accessible to people with disabilities, family ...
(Date:12/2/2008)...available to seniors , , DETROIT, Dec. 2 /P...P) is adding acupuncture and chiropractic services...re Advantage members beginning January 1, 2009. HA...ncourages Medicare beneficiaries to choose activit...ck in their wallets. , , HAP offers a Flex...
Breaking Medicine News(10 mins):Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 2Health News:Courion Helps Reduce Costs at Nation's Largest Operator of Senior Living Communities 3Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:New Website Links People With Disabilities to Peers for Help 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...analyzing the neuronal receptor activity in the po...enia, researchers at the University of Pennsylvani...ntists at the City University of New York, have fo...igh level of erbB4 receptor activity and reduced N...
...ding to the infectious disease expert the afro Ame...an papillomavirus (HPV). This vaccine was recently...ced in the Lancet Infectious Disease by researcher...al School. They said that the best ay for distri...
...al evidence of Huntington disease curing medicine ...f British Columbia's Centre for Molecular // Medic...h mouse. This provided hope in curing the disease ...urnal, Dr. Michael Hayden and colleagues discovere...
...elaide, Frozen pasta (such as frozen Beef Ravioli ...oisoning in six people //. The classical symptoms...iarrhoea.South Australian Health Department public...due to non-removal of the shell and eating the pro...
Other Medicine News:Health News:Schizophrenia Complicates With Altered Receptor Activity 2Health News:Schizophrenia Complicates With Altered Receptor Activity 3Health News:Afro American Women at a High Risk of HPV and Hence Should Be Vaccinated 2Health News:Animal Study Found Cure For Huntington Disease 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: